Astellas’ Vaprisol Approved For “Water Poisoning” Indication
This article was originally published in The Pink Sheet Daily
Executive Summary
Arginine vasopressin antagonist is the first drug indicated for the treatment of euvolemic hyponatremia.
You may also be interested in...
Cornerstone’s Hyponatremia Therapy Lixivaptan Will Get Advisory Panel Scrutiny
The hyponatremia drug is a selective vasopressin V2-receptor antagonist, like Astellas’ Vaprisol and Otsuka’s Samsca.
Astellas' Vaprisol Receives Second Indication
FDA has approved Astellas Pharma's Vaprisol (conivaptan) for the intravenous treatment of hospitalized patients with hypervolemic hyponatremia, the Japanese company announced March 2
Astellas’ Vaprisol Receives Second Indication
Vasopressin antagonist clears FDA for treatment of hospitalized patients with hypervolemic hyponatremia.